For the 1st nine months of 2013, the Company recognized a loss of $1.2 million for its equity interest in CML. The operating results of CML in 2013 have so far been adversely impacted by restructuring at the Ministry of Health, uncertainty surrounding proposed government reforms and the disruption to normal hospital purchasing activity due to the government campaign to boost compliance in the general public hospitals' purchasing activities, which provides led to an overall slowdown running a business activity among capital medical equipment markets in China. Non-GAAP Measures The Company presents Adjusted EBITDA to better illustrate ongoing operational outcomes.To our knowledge, just a small percent of biotech businesses in the world established Quality Administration Systems conforming to ISO specifications and subsequently obtained qualification. Related StoriesResearchers successfully restoration nerve cell harm in Alzheimer's dementiaData shows romosozumab much better than teriparatide in increasing bone power in postmenopausal womenJEDI T-cells offer unique technology to review, visualize immune responses and immunotherapiesSince its inception in 2005, Beike offers been centered on establishing rigorous quality control specs and systems for stem cell industrialization.